Program
prabotulinumtoxin A
Also written as “ABP-450”, “PrabotulinumtoxinA-Xvfs” and “DWP450”.
Its studies are mostly in Migraine Disorders · Torticollis, led by 3 companies.
Drug pagePrabotulinumtoxin A: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AEON Biopharma | 40 open or running | phase 2since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| Daewoong Pharmaceuticalits history only | 31 open or running | phase 3since Mar 2, 2020 | Mar 2, 2020 | May 2028phase 3 · NCT07783763 |
| Evolusits history only | 20 open or running | phase 2since Apr 21, 2015 | Apr 21, 2015 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP and ethica Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AEON Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2021First study: phase 2 study in Migraine DisordersFirst studyNCT04845178 · 797 enrolled · United States, Australia, Canada
- Apr 14, 20212 phase 2 studies in TorticollisNCT04849988, NCT04871451
- Aug 17, 2021Phase 2 study in Migraine DisordersNCT05016661 · 466 enrolled · United States, Australia, Canada
TargetBeta
“Synaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme”ChEMBL 37, by rule
Other programs on SNAP25
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| botulinum toxin type A | AbbVie | phase 4 | 286 |
| trenibotulinumtoxinErule | AbbVie | phase 3 | 11 |
Studies
All 4 AEON Biopharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05016661Migraine Disorders · United States, Australia, Canada | 2 | Terminated | Jul 31, 2024 | 466 |
| NCT04871451Torticollis · United States | 2 | Completed | Jul 24, 2023 | 51 |
| NCT04849988Torticollis · United States | 2 | Completed | Jul 11, 2022 | 61 |
| NCT04845178Migraine Disorders · United States, Australia, Canada | 2 | Completed | Jun 19, 2024 | 797 |
How it is read
Names in the registry
- “ABP-450”, 4 entries
- “PrabotulinumtoxinA-Xvfs”, 2 entries
- “DWP450”, 2 entries
- “DWP450 20 U”, 1 entry
- “DWP-450 (Botulinum purified neurotoxin, Type A)”, 1 entry
Conditions, from the studies’ own filings
- Migraine Disorders, 2 studies
- Torticollis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.